Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company was founded to help stop the current coronavirus pandemic (COVID-19) and prevent the next. Pardes scientists developed a novel oral antiviral treatment for COVID-19, pomotrelvir, from concept through phase 2 testing in under three years. In addition, our research efforts have generated highly potent new chemical entities with broad spectrum pan-coronavirus activity to help better prepare for future threats. Our lead program, pomotrelvir, our research assets, and intellectual property are available for partnering while the company explores a range of strategic alternatives. Contact us here.